JP2002532067A5 - - Google Patents

Download PDF

Info

Publication number
JP2002532067A5
JP2002532067A5 JP2000584053A JP2000584053A JP2002532067A5 JP 2002532067 A5 JP2002532067 A5 JP 2002532067A5 JP 2000584053 A JP2000584053 A JP 2000584053A JP 2000584053 A JP2000584053 A JP 2000584053A JP 2002532067 A5 JP2002532067 A5 JP 2002532067A5
Authority
JP
Japan
Prior art keywords
ribonuclease
modified
amino acid
sterically hindered
hindered moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000584053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532067A (ja
JP4731015B2 (ja
Filing date
Publication date
Priority claimed from US09/199,242 external-priority patent/US6280991B1/en
Application filed filed Critical
Publication of JP2002532067A publication Critical patent/JP2002532067A/ja
Publication of JP2002532067A5 publication Critical patent/JP2002532067A5/ja
Application granted granted Critical
Publication of JP4731015B2 publication Critical patent/JP4731015B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000584053A 1998-11-24 1999-11-22 改変細胞傷害性リボヌクレアーゼ Expired - Fee Related JP4731015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/199,242 1998-11-24
US09/199,242 US6280991B1 (en) 1997-10-15 1998-11-24 Engineered cytotoxic ribonclease
PCT/US1999/027670 WO2000031242A2 (en) 1998-11-24 1999-11-22 Engineered cytotoxic ribonuclease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010271615A Division JP2011078428A (ja) 1998-11-24 2010-12-06 改変細胞傷害性リボヌクレアーゼ

Publications (3)

Publication Number Publication Date
JP2002532067A JP2002532067A (ja) 2002-10-02
JP2002532067A5 true JP2002532067A5 (https=) 2007-01-18
JP4731015B2 JP4731015B2 (ja) 2011-07-20

Family

ID=22736771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000584053A Expired - Fee Related JP4731015B2 (ja) 1998-11-24 1999-11-22 改変細胞傷害性リボヌクレアーゼ
JP2010271615A Abandoned JP2011078428A (ja) 1998-11-24 2010-12-06 改変細胞傷害性リボヌクレアーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010271615A Abandoned JP2011078428A (ja) 1998-11-24 2010-12-06 改変細胞傷害性リボヌクレアーゼ

Country Status (7)

Country Link
US (1) US6280991B1 (https=)
EP (1) EP1131417A2 (https=)
JP (2) JP4731015B2 (https=)
AU (1) AU778024B2 (https=)
CA (1) CA2351735C (https=)
IL (2) IL143036A0 (https=)
WO (1) WO2000031242A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489446A1 (en) * 2002-06-14 2003-12-24 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
WO2004085611A2 (en) * 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7655757B2 (en) * 2005-06-16 2010-02-02 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
WO2006138458A1 (en) * 2005-06-16 2006-12-28 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
WO2007041361A1 (en) * 2005-09-30 2007-04-12 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Modified recombinant anti-tumor rnase
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US8069251B2 (en) * 2007-06-01 2011-11-29 Adobe Systems Incorporated System and/or method for client-driven server load distribution
EP2205271B1 (en) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
WO2009088992A2 (en) * 2008-01-07 2009-07-16 University Of Vermont And State Agricultural College Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
US8029782B2 (en) 2008-10-01 2011-10-04 Quintessence Biosciences, Inc. Therapeutic ribonucleases
KR101934923B1 (ko) 2009-11-02 2019-04-10 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
PH12013502441B1 (en) 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
ES2971441T3 (es) * 2016-05-06 2024-06-05 Biodynamic Res Foundation Composición farmacéutica que contiene un fármaco macromolecular
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
US11286469B2 (en) 2017-11-09 2022-03-29 Wisconsin Alumni Research Foundation Combination chemotherapy for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840840A (en) 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
US5389537A (en) 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity
US5840296A (en) * 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A

Similar Documents

Publication Publication Date Title
JP2002532067A5 (https=)
JP4280070B2 (ja) 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
WO2002047715A3 (en) Compositions of peptide crystals
DK1105409T3 (da) Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
JP2004520395A5 (https=)
CA2122717A1 (en) Hemoglobins as drug delivery agents
DE69334266D1 (de) Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate
CA2363712A1 (en) Long lasting insulinotropic peptides
MXPA97007050A (es) Derivados de hormona pepticida lipofilica.
ATE375363T1 (de) Derivate des wachstumshormons und verwandte proteine
FI911319A0 (fi) Polypeptidderivat.
IL124831A0 (en) Ob protein derivatives having prolonged half-life
WO2001036001A3 (en) Interferon gamma conjugates
NO992557D0 (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
CA2331337A1 (en) Site specific protein modification by mutagenesis
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
EP2278003A3 (en) Method for controlling the activity of immunologically functional molecule
CA2351735A1 (en) Engineered cytotoxic ribonuclease
PT1146896E (pt) Formulacoes monodispersas de analogo acilado e hexamerico insulina
EA200301017A1 (ru) Использование конъюгатов желчной кислоты или соли желчной кислоты с жирными кислотами
WO2001015736A3 (en) Interferon-beta conjugates
BG104539A (en) Ifnar-2/ifn complex
JP2001516567A5 (https=)
WO1999027948A3 (en) Use of soluble recombinant human cd40l protein for inhibiting in vivo immune response
WO2002058589A3 (en) Agents and methods for promoting bone growth